drugset / Trial / NCT02112500

Mesenchymal Stem Cell in Patients With Acute Severe Respiratory Failure

NCT02112500

Phase 2 Unknown 10 enrolled Asan Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Although the advent of advanced medical support for respiratory failure, the mortality rate of acute severe respiratory failure is still high and the life quality is frequently compromised from pulmonary fibrosis. The investigators hypothesize that the treatment using mesenchymal stem cell can be beneficial in patients with respiratory failure. The present study is a pilot study evaluating the efficacy and safety of mesenchymal stem cell treatment in patients with respiratory failure.

Timeline

Start
2014-02
Primary completion
2016-12
Completion
2016-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesenchymal stem cell Cell therapy Intravenous